CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者 Revenue and Competitors

Taipei city,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者's estimated annual revenue is currently $7M per year.(i)
  • CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者's estimated revenue per employee is $251,000

Employee Data

  • CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者 has 28 Employees.(i)
  • CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者 grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is CHC承業生醫(4164) 亞太地區綜合性醫療設備、技術及服務產業領導者?

The first subsidiary of CHC Healthcare Group (CHC) was established in 1977, with nearly 20 domestic and overseas subsidiaries, CHC was successfully listed at Taiwan Stock Exchange in October 2012 with stock code 4164. With over 40 years of expertise in providing comprehensive healthcare management services including equipment collaboration, management consultation, hospital department management, and operations management for medical institutions, CHC is the preferred choice of partner for many medical institutions. In order to sustain consistent growth in performance, CHC investment holding company is responsible for oversee and manage all of its subsidiaries, and with integration of resources, CHC is able to elevate efficiency and performance of the company. Furthermore, by maintain a strong tie with investor's relationship with a sounding financial funding structure, CHC ensures maintaining as a leader in the healthcare industry.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M288%N/A
#2
$3.4M307%N/A
#3
$4.1M37-5%N/A
#4
$4.6M40N/AN/A
#5
$4.9M422%N/A